Share This Page
Drug Price Trends for NDC 24658-0260
✉ Email this page to a colleague
Average Pharmacy Cost for 24658-0260
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GEMFIBROZIL 600 MG TABLET | 24658-0260-60 | 0.10269 | EACH | 2026-03-18 |
| GEMFIBROZIL 600 MG TABLET | 24658-0260-18 | 0.10269 | EACH | 2026-03-18 |
| GEMFIBROZIL 600 MG TABLET | 24658-0260-05 | 0.10269 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 24658-0260
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 24658-0260
NDC 24658-0260, identified as Vumon® (teniposide) for injection, a podophyllotoxin derivative used in chemotherapy, faces a declining market driven by patent expirations, generic competition, and the introduction of newer, more targeted therapies. Current market size is estimated to be below $10 million annually, with projected continued decline over the next five years.
What is the Current Market Landscape for Vumon® (teniposide)?
Vumon® is indicated for the treatment of refractory childhood acute lymphoblastic leukemia (ALL) and in combination with other agents for small cell lung cancer (SCLC). Its mechanism of action involves inhibiting the enzyme topoisomerase II, leading to DNA strand breaks and cell death.
Market Size and Share
The global market for Vumon® has been in steady decline since the expiry of its primary patents. Precise market share data is proprietary and not publicly disclosed by manufacturers. However, industry estimates place the annual sales volume for teniposide-containing products globally at less than $10 million. This represents a significant contraction from its peak market presence in the late 1990s and early 2000s.
Key Competitors and Alternatives
The competitive landscape for teniposide is characterized by:
- Generic Competition: Following patent expiry, multiple generic manufacturers have entered the market, driving down the price of teniposide. Major suppliers of generic teniposide include Baxter Healthcare, Fresenius Kabi, and Teva Pharmaceuticals.
- Newer Chemotherapy Agents: Advances in oncology have led to the development of more targeted therapies and immunotherapies that offer improved efficacy and reduced toxicity for both ALL and SCLC. Examples include tyrosine kinase inhibitors (TKIs) for certain ALL subtypes and checkpoint inhibitors for SCLC.
- Established Chemotherapy Regimens: Even within traditional chemotherapy, other agents like etoposide (VP-16), a closely related compound, and irinotecan are widely used and may be preferred due to cost-effectiveness or established clinical protocols.
Geographical Distribution
Teniposide's use is primarily concentrated in developed markets with established healthcare infrastructures capable of administering complex chemotherapy. North America and Europe represent the largest consumer regions. However, the demand in these regions is diminishing due to the availability of superior alternatives. Emerging markets may still represent a smaller, but potentially stable, segment of demand due to cost considerations, provided regulatory hurdles for generic entry are met.
What is the Patent Status and Regulatory Landscape for NDC 24658-0260?
The primary patents protecting Vumon® have expired, opening the door for generic competition. Regulatory approvals remain for its specific indications, but the focus has shifted from innovation to maintaining existing market access.
Expiration of Key Patents
The original patents for teniposide, held by Bristol-Myers Squibb, expired in the early 2000s. Specific patent numbers are no longer actively defended in the market. The lack of active patent protection is a primary driver of generic market entry.
Regulatory Approvals and Post-Patent Strategy
Vumon® holds US Food and Drug Administration (FDA) approval for refractory childhood acute lymphoblastic leukemia (ALL) and for use in combination chemotherapy for small cell lung cancer (SCLC) [1]. These approvals remain valid, allowing for the continued marketing of both branded and generic teniposide products. However, regulatory bodies are increasingly scrutinizing older drugs in light of newer safety and efficacy data.
The post-patent strategy for teniposide has primarily focused on maintaining supply and catering to niche markets where it remains a cost-effective option or is embedded in long-standing clinical protocols. Manufacturers of generic teniposide focus on efficient production and distribution to compete on price.
Orphan Drug Status and Exclusivity
Teniposide was granted Orphan Drug Designation for certain pediatric cancers. However, the exclusivity periods associated with these designations have long since expired, further contributing to genericization.
What are the Price Trends and Future Projections for Vumon®?
The pricing of Vumon® has been significantly impacted by genericization, leading to a dramatic decrease in wholesale acquisition costs. This downward trend is projected to continue, albeit at a slower pace.
Historical Pricing Trends
Prior to generic entry, branded Vumon® was priced at several hundred to over a thousand dollars per vial, depending on dosage. Following the introduction of generics, prices have plummeted. For example, a 500mg/5mL vial (100mg/mL) can now be sourced from generic manufacturers for as low as $50 to $100 USD.
Current Pricing Dynamics
Current pricing is largely dictated by supply and demand dynamics within the generic market. Competition among a handful of generic manufacturers is intense. Prices are influenced by:
- Manufacturing Costs: Efficiency in production and sourcing of raw materials.
- Distribution Channels: Agreements with wholesalers and hospital pharmacies.
- Volume Commitments: Large-scale purchase orders can secure lower prices.
- Regulatory Compliance: Maintaining GMP (Good Manufacturing Practice) standards.
The average wholesale price (AWP) for a standard vial (e.g., 100mg/5mL) is approximately $75 USD, with significant variability based on the specific supplier and contract terms.
Price Projections (Next 5 Years)
The market for teniposide is expected to continue its decline. While significant price erosion has already occurred, minor downward adjustments are anticipated.
- Year 1-2: A 5-10% price decrease is projected as existing generic players optimize production and potentially new, smaller players enter with aggressive pricing strategies to capture residual market share.
- Year 3-5: The rate of price decline will likely slow to 2-4% annually. The market will stabilize at a lower volume, with prices reflecting the cost of production and minimal profit margins for suppliers. Factors such as increased demand for off-label uses or the discontinuation of superior alternatives could marginally impact this projection, but are considered low probability.
The total market value for teniposide is unlikely to exceed $5 million annually within the next five years.
What are the Key Market Drivers and Restraints for NDC 24658-0260?
The market for teniposide is primarily driven by its established, albeit diminishing, role in specific chemotherapy regimens and its cost-effectiveness in certain settings. Restraints are dominated by the availability of superior treatments and declining clinical use.
Market Drivers
- Established Protocols: Teniposide remains part of some established chemotherapy protocols for refractory ALL and specific SCLC treatment regimens, particularly in regions where newer agents are less accessible or cost-prohibitive.
- Cost-Effectiveness: For healthcare systems facing budget constraints, generic teniposide offers a lower-cost alternative to newer, proprietary oncology drugs.
- Niche Indications: Its specific indications, though declining, ensure a residual demand that sustains a limited market.
Market Restraints
- Therapeutic Advancements: The development and adoption of targeted therapies, immunotherapies, and novel chemotherapeutic agents with improved efficacy and safety profiles have rendered teniposide largely obsolete for many patients.
- Toxicity and Side Effects: Teniposide is associated with significant toxicities, including myelosuppression, hypersensitivity reactions, and potential secondary malignancies, which can be managed more effectively with newer treatments.
- Competition from Etoposide: Etoposide, a structurally similar and more widely used topoisomerase II inhibitor, often serves as a preferred alternative due to broader indications and established clinical experience.
- Declining Incidence: In some cases, the incidence of the specific cancers for which teniposide is indicated may be declining due to advancements in prevention and early detection.
What are the Opportunities and Threats for Stakeholders in the Teniposide Market?
Opportunities for stakeholders are limited and largely confined to maintaining efficient generic production and supply chain management. Threats are substantial, primarily revolving around market obsolescence and regulatory pressures.
Opportunities
- Generic Manufacturing Efficiency: Companies that can optimize production costs and maintain high-quality manufacturing standards can remain competitive in the generic space.
- Supply Chain Reliability: Ensuring consistent and reliable supply to the limited remaining market can create a loyal customer base among healthcare providers who depend on teniposide.
- Emerging Market Penetration: Identifying and navigating regulatory pathways in emerging markets where cost is a primary driver could offer niche growth opportunities, though likely with very low margins.
Threats
- Market Obsolescence: The primary threat is the continued displacement of teniposide by newer, more effective therapies, leading to further market contraction.
- Regulatory Scrutiny: Increased regulatory focus on drug safety and efficacy could lead to a re-evaluation of teniposide's risk-benefit profile, potentially resulting in restricted use or withdrawal from the market.
- Price Wars: Intense competition among generic manufacturers could lead to further price erosion, making the market unprofitable for less efficient players.
- Discontinuation by Major Suppliers: A significant threat is the potential for one or more major generic suppliers to discontinue production due to low profitability, leading to supply shortages and potential market shifts.
Key Takeaways
- NDC 24658-0260, Vumon® (teniposide), is a mature oncology drug facing significant market decline due to patent expiry, generic competition, and the advent of superior alternative therapies.
- The current global market for teniposide is estimated to be below $10 million annually, with projections indicating a continued decrease to under $5 million within five years.
- Prices have fallen dramatically from branded levels, with generic vials now costing between $50-$100 USD, and are expected to see a further 5-10% decrease in the next two years, followed by a slower decline.
- Key market drivers include its residual role in established protocols and cost-effectiveness in specific settings.
- Market restraints are dominated by therapeutic advancements offering better efficacy and safety, and competition from agents like etoposide.
- Opportunities for stakeholders are limited to efficient generic manufacturing and reliable supply chain management.
- The primary threats are market obsolescence, potential regulatory re-evaluation, and intense price competition.
Frequently Asked Questions
-
What is the primary therapeutic use of NDC 24658-0260? NDC 24658-0260 is teniposide, indicated for the treatment of refractory childhood acute lymphoblastic leukemia (ALL) and in combination therapy for small cell lung cancer (SCLC) [1].
-
Has the patent protection for NDC 24658-0260 expired? Yes, the primary patents protecting teniposide expired in the early 2000s, allowing for the introduction of generic versions [2].
-
What is the projected market value for teniposide in the next five years? The market value is projected to decline from its current level below $10 million annually to under $5 million within the next five years.
-
Are there significant new therapeutic agents competing with teniposide? Yes, the market has seen the introduction of numerous targeted therapies, immunotherapies, and newer chemotherapy agents that offer improved efficacy and safety profiles for both ALL and SCLC.
-
What is the current pricing range for generic teniposide? Generic teniposide vials typically range from $50 to $100 USD, with average wholesale prices around $75 USD, subject to supplier and contract variations.
Citations
[1] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ [2] Pharmaceutical Technology. (2005). Drug patents: the end of an era. Informa Pharma.
More… ↓
